Skip to content
Screener

Monopar Therapeutics MNPR Q4 2025 Annual earnings

Reported March 27, 2026 · Before market open

Revenue-
EPS-$0.61Miss by $0.10
EPS estimate-$0.51

Next report

Nov 6, 2026 (in 3 months)
EPS estimate-$0.77

Financials

Q4 2025

Income statement

See full
Revenue-—
Operating income-$6.2M+44.4%
Net income-$5.2M+52.4%

Balance sheet

See full
Cash & equivalents$61.8M+35.0%
Total debt$245.5K—
Total equity$137.8M+150%
Total assets$140.7M+133%

Cash flow

See full
Operating cash flow-$3.4M-68.6%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$436.37M+225%
Enterprise value$374.78M—

Returns & leverage

See full
Return on equity-14.2%-6.0pp
Debt / equity0×—
Current ratio51.4×+39.9×

FAQ

When did Monopar Therapeutics report Q4 2025 earnings?
Monopar Therapeutics (MNPR) reported Q4 2025 earnings on March 27, 2026 before market open.
What were Monopar Therapeutics's Q4 2025 revenue and EPS?
Monopar Therapeutics reported revenue of - and eps of $-0.61 for Q4 2025.
Did Monopar Therapeutics beat estimates in Q4 2025?
EPS missed the consensus estimate of $-0.51 by $0.10.
How did Monopar Therapeutics's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 72.6% from $-2.23.
Where can I find Monopar Therapeutics's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001437749-26-010030) and the 10-K periodic report (0001437749-26-010025) directly on SEC EDGAR. The filing index links above go to sec.gov.